%0 Journal Article %A Muhammad Asim Rana %A Ahad Qayyum %A Mubashar Hashmi %A Muhammad Muneeb Ullah Saif %A Muhammad Faisal Munir %A Rizwan Pervaiz %A Muhammad Mansoor Hafeez %T Mortality & COVID-19: A Snapshot of a Tertiary Care Facility in Pakistan %D 2020 %R 10.1101/2020.08.25.20181792 %J medRxiv %P 2020.08.25.20181792 %X Introduction Ever since Sars CoV-2 infection has started from China and has taken the shape of pandemic the mortality associated with this disease has been under discussion and hypercoagubility, acute severe respiratory syndrome and sepsis with multi organ failure have been accursed as possible reasons of deaths in cases infected with novel Corona virus. We conducted a retrospective analysis of the cases admitted in our high dependency and Intensive care unit and tried to pinpoint the major cause of mortality in our cases.Methods This is a single center retrospective study carried out at Bahria International Hospital Lahore over a 3 month period (May 10th to July 10th 2020) in which we analyzed the clinical and biochemical profiles of the COVID-19 patients who died during this period.Results A total of 108 patients were admitted during this period out of which 11 patients died. 7 of them were men and 4 women. Majority of them had sudden cardiac arrest due to acute coronary syndrome followed by multiorgan dysfunction syndrome and acute respiratory distress syndrome.Conclusion Acute coronary syndrome due to hypercoagubility was the leading cause of death in our patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding of any kind has been obtained for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Internal Review Board and Ethical Committee of Bahria International Hospital has approved this study to be conducted in its vicinity via letter No: IRBEC/BIH/covid19/021-20202All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available with the IRB&EC of Hospital %U https://www.medrxiv.org/content/medrxiv/early/2020/08/31/2020.08.25.20181792.full.pdf